Article info
PDFClinical and epidemiological research
Extended report
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
- Correspondence toNathan Vastesaeger, Department of Immunology, MSD, Rue de Stalle 73, B-1180, Brussels, Belgium; nathan.vastesaeger{at}merck.com
Citation
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
Publication history
- Accepted August 27, 2011
- First published October 12, 2011.
Online issue publication
October 25, 2017
Web Only Data
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl